Willingness to Participate in HIV Therapeutic Vaccine Trials among HIV-Infected Patients on ART in ChinaReport as inadecuate




Willingness to Participate in HIV Therapeutic Vaccine Trials among HIV-Infected Patients on ART in China - Download this document for free, or read online. Document in PDF available to download.

Background

More and more HIV therapeutic vaccines will enter clinical trials; however, little is known about the willingness to participate WTP in HIV therapeutic vaccine trials among HIV-positive individuals.

Objective

To investigate the WTP in HIV therapeutic vaccine trials among Chinese HIV-infected patients.

Methods

We conducted a cross-sectional survey on HIV-positive inpatients and outpatients at Shanghai Public Health Center. A total of 447 participants were recruited into this study. Following an introduction with general information on HIV therapeutic vaccine and its potential effectiveness and side effects, each participant completed a questionnaire in a self-administered form. The questionnaires covered demographics, high-risk behaviors, clinical characteristics and willingness to participate in HIV therapeutic vaccine trial.

Results

The overall willingness to participate in HIV therapeutic vaccine trials was 91.5%. Interestingly, multivariate logistic regression analyses demonstrated that the willingness was higher for those sexually infected by HIV odds ratio OR: 4.36; 95% confidence interval CI: 1.53–12.41, diagnosed as HIV-1 infection for greater than 5 years OR: 7.12, 95% CI: 1.83–27.76, and with the presence of infectious complications OR: 2.75; 95% CI: 1.02–7.45. The primary reason for participation was to delay or reduce antiretroviral treatment ART and to avoid ART side effects 76.6%, and then followed by delaying disease progression 74.9%, increasing immune response to suppress opportunistic infections 57.7% and preventing the development of drug resistance 37.1%. Reasons for unwillingness to participate mainly included concern for safety 37.0%, lack of knowledge on therapeutic vaccine 33.3%, and satisfaction with ART effectiveness 22.2%.

Conclusions

The WTP in HIV therapeutic vaccine trials was high among HIV-infected Chinese patients. HIV+ subjects who acquired infection through sexual contact and who were diagnosed for more than 5 years may represent a good candidate population for enrollment in therapeutic vaccine trials.



Author: Yuan Dong, Xiaoxing Shen, Ruizhang Guo, Baochi Liu, Lingyan Zhu, Jing Wang, Linxia Zhang, Jun Sun, Xiaoyan Zhang , Jianqing Xu

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents